CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR-T cell combination therapies in hematologic malignancies.
CAR-T cell combination therapies in hematologic malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 是癌症治疗的重要突破,在血液恶性肿瘤中疗效显著,但单药治疗仍可能面临耐受和复发。研究者正探索与其他疗法联合以增强疗效。本文综述CAR-T 联合治疗血液肿瘤的研究进展,涵盖治疗基本原理及临床应用,并讨论其与化疗、免疫检查点抑制剂、靶向药物、放疗、造血干细胞移植及其他疗法的组合。不同机制的治疗联合可协同增强CAR-T 抗肿瘤作用,从而改善患者应答和生存。
Chimeric antigen receptor-T cell therapy, a groundbreaking cancer treatment, has achieved remarkable success against hematologic malignancies.
However, CAR-T monotherapy faces challenges in certain cases, including treatment tolerance and relapse rates. To overcome these challenges, researchers are investigating combining CAR-T cells with other treatments to enhance therapeutic efficacy.
Therefore, this review aims to investigate the progress of research in combining CAR-T cells for hematologic malignancies. It covers the basic principles and clinical applications of CAR-T cell therapy, detailing combinations with chemotherapy, immune checkpoint inhibitors, targeted drugs, radiotherapy, hematopoietic stem cell transplantation, and other treatments. These combinations synergistically enhance the antitumor effects of CAR-T cells and comprehensively target tumors through different mechanisms, improving patient response and survival rates.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。